Insider Buying: Daxor Co. (NASDAQ:DXR) CEO Buys 2,063 Shares of Stock

Daxor Co. (NASDAQ:DXR) CEO Michael Richard Feldschuh bought 2,063 shares of the firm’s stock in a transaction dated Friday, April 4th. The shares were acquired at an average price of $7.89 per share, for a total transaction of $16,277.07. Following the completion of the transaction, the chief executive officer now directly owns 212,694 shares in the company, valued at approximately $1,678,155.66. This represents a 0.98 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Michael Richard Feldschuh also recently made the following trade(s):

• On Monday, March 10th, Michael Richard Feldschuh bought 3,360 shares of Daxor stock. The stock was purchased at an average cost of $7.68 per share, for a total transaction of $25,804.80.

Daxor Trading Down 2.5 %

Daxor stock traded down $0.19 during mid-day trading on Monday, reaching $7.45. 3,899 shares of the company traded hands, compared to its average volume of 7,245. The firm’s fifty day moving average is $7.76 and its two-hundred day moving average is $8.38. Daxor Co. has a fifty-two week low of $6.55 and a fifty-two week high of $10.00.

Institutional Investors Weigh In On Daxor

An institutional investor recently raised its position in Daxor stock. Renaissance Technologies LLC lifted its position in Daxor Co. (NASDAQ:DXR) by 87.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,821 shares of the company’s stock after acquiring an additional 13,000 shares during the period. Renaissance Technologies LLC owned 0.57% of Daxor worth $214,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 1.34% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets upped their price target on shares of Daxor from $24.75 to $25.00 and gave the stock a “buy” rating in a research report on Monday, March 17th.

Daxor Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.